Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals  Endpoints NewsBREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions  Psychedelic AlphaBiotech Led Health Care’s Choppy Trading Session  FinimizeCMPS: COMP360 showed rapid, durable efficacy and strong safety in TRD, with launch preparations underway  TradingViewRobust Phase 3 Efficacy and Clean Safety Profile Drive Buy Rating on COMPASS Pathways’ CMPS  TipRanks